Chris Ryan
A federal jury in Delaware reportedly found that Japan’s Nippon Shinyaku Corporation violated the Sarepta Act (Nasdaq:SRPT) patented the Duchenne muscular dystrophy, or DMD, drug Vyondys 53 and awarded Sarepta $115.2 million in damages.
The jury also rejected Shinyaku’s claim
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/104821184/image_104821184.jpg?io=getty-c-w750
Source link